Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03582176 · ClinicalTrials.gov registry record · Phase 3
PrEvention of Posttraumatic Joint contractuRes With Ketotifen 2
A Phase 3 study of Elbow Dislocation and Elbow Injury, sponsored by University of Calgary.
- Completed
- Registry status
- Phase 3
- Development phase
- 395
- Enrollment target
- 15
- Study locations
NCT03582176: Completed Phase 3 study of Elbow Dislocation and Elbow Injury, sponsored by University of Calgary.
NCT03582176 is a Phase 3 study of Elbow Dislocation and Elbow Injury that has completed, run by University of Calgary. The registered enrollment target is 395 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (49% lower). The trial reports 15 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03582176, a Phase 3 study of Elbow Dislocation and Elbow Injury, has completed, sponsored by University of Calgary.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 395 participants
- Enrollment target
- 15
- Study locations
Study Summary
PrEvention of posttraumatic contractuRes with Ketotifen 2 (PERK 2) is a Phase III randomized, controlled, double blinded multicenter trial with 3 parallel groups (Ketotifen 2 mg or 5 mg or lactose placebo twice daily orally for 6 weeks) and a primary endpoint of elbow extension-flexion range of motion (ROM) arc at 12 weeks post-randomization.
Primary Outcome
The change in range of motion between baseline and 12 weeks post-randomization
Conditions Studied
Interventions
- DRUG Lactose Placebo
- DRUG Ketotifen Fumarate 2mg
- DRUG Ketotifen Fumarate 5mg
Study Locations (15)
Ontario
- St. Joseph's Health Care London - London
- The Ottawa General Hospital - Ottawa
- The Ottawa Civic Hospital - Ottawa
- Sunnybrook Health Sciences Centre - Toronto
- St. Michael's Hospital - Toronto
Alberta
- Peter Lougheed Centre - Calgary
- Foothills Medical Centre - Calgary
- South Health Campus - Calgary
- Sturgeon Community Hospital - St. Albert
British Columbia
- Royal Columbia Hospital - New Westminster
- St. Paul's Hospital - Vancouver
Maryland
- University of Maryland Medical Centre - Baltimore
North Carolina
- Carolinas Medical Center - Charlotte
Vermont
- University of Vermont Medical Center - Burlington
Nova Scotia
- Queen Elizabeth II Health Sciences Centre - Halifax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 395 participants |
| Start Date | 2019-04-26 |
| Est. Completion | 2024-12-17 |
| Phase | Phase 3 |
What the finished NCT03582176 record still lists
NCT03582176 is an interventional study that assigns participants to a tested intervention. The registered 395 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (49% lower).
The record links to 3 conditions, with Elbow Dislocation appearing as the primary indexed condition, and to 3 interventions - of which Lactose Placebo is the first listed.
NCT03582176 lists 15 locations in 7 states (Ontario, Alberta, British Columbia).
Frequently Asked Questions
What is clinical trial NCT03582176 about?
NCT03582176 is a clinical study titled "PrEvention of Posttraumatic Joint contractuRes With Ketotifen 2". PrEvention of posttraumatic contractuRes with Ketotifen 2 (PERK 2) is a Phase III randomized, controlled, double blinded multicenter trial with 3 parallel groups (Ketotifen 2 mg or 5 mg or lactose placebo twice daily orally for 6 weeks) and a primary endpoint of elbow extension-flexion range of moti...
What is the current status of trial NCT03582176?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 395 participants. The study started on 2019-04-26. Estimated completion is 2024-12-17.
What conditions does trial NCT03582176 study?
This clinical trial studies the following conditions: Elbow Dislocation, Elbow Injury, Elbow Fracture.
What interventions are being tested in trial NCT03582176?
The interventions under investigation include: Lactose Placebo (DRUG), Ketotifen Fumarate 2mg (DRUG), Ketotifen Fumarate 5mg (DRUG).
Who is sponsoring clinical trial NCT03582176?
This trial is sponsored by University of Calgary, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03582176 being conducted?
This trial has 15 study locations across Maryland, North Carolina, Vermont, Alberta, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Elbow Dislocation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03582176's enrollment target sits among peer trials
395 965th of 2000 higher than 1,034 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07207369 · 395 participants · Phase 3
A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars
- NCT05633615 · 396 participants · Phase 2
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06227910 · 396 participants · Phase 3
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- NCT06545331 · 396 participants · Phase 1
Study of XB010 in Subjects With Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI